Bluebird bio is emerging from the other side of a private equity buyout and shedding its feathers. The gene therapy company ...

BMO Capital Markets analysts said the first day of the CDC vaccine advisors Thursday had anti-vaccine overtones as the panel, ...

The House Committee on Energy and Commerce has cleared proposed legislation that could bring back the FDA’s rare pediatric ...

Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to ...

Both BMS and Novo Nordisk have, in recent months, announced steep layoffs as they strive to cut back on costs.

The star of the acquisition, which includes a contingent value right of $6 per share, is pegozafermin, an FGF21 analog in ...

DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental ...

In this episode of Denatured, BioSpace’s head of insights Lori Ellis and Colin Zick, partner at Foley Hoag LLP, spend time ...

Supporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage ...

Brepocitinib remains “ahead of competition” in the dermatomyositis space, according to analysts at Leerink, who projected ...

This year, Novo Nordisk and Merck announced significant layoffs, with Novo planning to axe about 9,000 employees and Merck projecting it could let go of roughly 6,000. Meanwhile, Bayer, Bristol Myers ...

The sub-analysis, presented at the European Association for the Study of Diabetes congress, showed improved safety data to ...